Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 11/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129247 | 0.89 | GRM5 (0.48) | SMN1; SMN2HTTALDH1A1NPSR1GRM5 | |
| SCHEMBL5116497 | 0.88 | GRM5 (0.46) | SMN1; SMN2HTTALDH1A1NPSR1GRM5 | |
| SCHEMBL5128145 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2HTTALDH1A1NPSR1GRM5 | |
| SCHEMBL5123256 | 0.85 | CYP3A4 (0.47) | SMN1; SMN2HTTALDH1A1TSHRGRM5 | |
| SCHEMBL5130117 | 0.83 | GRM5 (0.44) | SMN1; SMN2HTTALDH1A1TSHRGRM5 | |
| SCHEMBL5128749 | 0.82 | NPC1 (0.48) | GRM5ENPP2ATXN2HPGD | |
| SCHEMBL5125308 | 0.81 | PKM (0.56) | GRM5ENPP2ATXN2LMNA | |
| SCHEMBL5128669 | 0.81 | SPR (0.42) | ALDH1A1GRM5ENPP2ATXN2 | |
| SCHEMBL5114700 | 0.80 | GRM5 (0.46) | GRM5 | |
| SCHEMBL5122268 | 0.78 | ENPP2 (0.48) | SMN1; SMN2ALDH1A1TSHRGRM5ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1856107-A1 | PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS | Novartis AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006089700-A1 | PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS | NOVARTIS AG (CH) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | GRM5, GRIK5, GRM1 | SMN1; SMN2 2698/4885HTT 1362/4885ALDH1A1 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.